70627-20-2Relevant articles and documents
Difluoroketenimine: Generation from Difluorocarbene and Isocyanide and Its [3 + 2] Cycloadditions with Alkenes or Alkynes
Zhang, Rui,Zhang, Zhikun,Wang, Kang,Wang, Jianbo
, p. 9791 - 9800 (2020)
Ketenimines have been explored as useful building blocks for the synthesis of heteroatom-containing cyclic compounds through the cycloaddition with polar multiple bonds. Herein, we report the cycloaddition of difluoroketenimine with nonpolar multiple bond
Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders
Dou, Xiaozheng,Nath, Dinesh,Shin, Henry,Nurmemmedov, Elmar,Bourne, Philip C.,Ma, Jian-Xing,Duerfeldt, Adam S.
, p. 2854 - 2876 (2020/04/10)
Peroxisome proliferator-activated receptor alpha (PPARα) is expressed in retinal Müller cells, endothelial cells, and in retinal pigment epithelium; agonism of PPARα with genetic or pharmacological tools ameliorates inflammation, vascular leakage, neurodegeneration, and neovascularization associated with retinal diseases in animal models. As such, PPARα is a promising drug target for diabetic retinopathy and age-related macular degeneration. Herein, we report proof-of-concept in vivo efficacy in an streptozotocin-induced vascular leakage model (rat) and preliminary pharmacokinetic assessment of a first-generation lead 4a (A91). Additionally, we present the design, synthesis, and evaluation of second-generation analogues, which led to the discovery of 4u and related compounds that reach cellular potencies 2,700-fold selectivity for PPARα over other PPAR isoforms. These studies identify a pipeline of candidates positioned for detailed PK/PD and pre-clinical evaluation.
NOVEL COMPOUNDS
-
Paragraph 0493; 0495, (2015/03/04)
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, X, m, R2, Y, R3, Z, n, R4, A and B are as defined in the specification, processes for their prep